Novo Nordisk accused in US court of delaying generic competition for GLP-1 drug
MLex Summary: Novo Nordisk has been accused in a US complaint of illegally delaying generic competition for its branded GLP-1 drug Victoza. The complaint claims that Novo used a delay it bought...To view the full article, register now.
Already a subscriber? Click here to view full article